Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in isocitrate dehydrogenase-mutant astrocytoma patients.

Neuro-oncology - 1 Aug 2026

Cho Minjee, Kim Minjin, Kim Hyeonjin, Choi Kaeum, Han Kyunghwa, Ahn Sung Soo, Yoon Hong In, Chang Jong Hee, Kim Se Hoon, Lee Seung-Koo, Park Yae Won, Pope Whitney B

Abstract excerpt

BACKGROUND: To comprehensively investigate clinical, molecular, radiological, and surgical factors for prediction of progression-free survival (PFS) in patients with isocitrate dehydrogenase (IDH)-mutant astrocytomas. METHODS: A total of 210 patients with newly diagnosed World Health Organization (WHO) grade 2-4 IDH-mutant astrocytomas between 2005 and 2023 were included. Clinical, molecular, radiological, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Follow-Up Studies

Share to Isocitrate Dehydrogenase

Share to Prognosis

Share to Survival Rate

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 42080952
DOI: 10.1093/neuonc/noag096
PMCID: PMC13437899

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in isocitrate dehydrogenase-mutant astrocytoma patients.PMID 42080952Read ↗

Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.Semantic proximity Read ↗

Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors.Semantic proximity Read ↗

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.Semantic proximity Read ↗

Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study.Semantic proximity Read ↗

Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratification.Semantic proximity Read ↗

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.Semantic proximity Read ↗

Expanding the molecular grading criteria in IDH-mutant astrocytoma.Semantic proximity Read ↗

Distinguishing IDH-mutant astrocytomas from IDH-wildtype glioblastomas using qualitative and quantitative MRI features: a WHO CNS5 study.Semantic proximity Read ↗

Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort Study.Semantic proximity Read ↗

An Analysis for IDH-Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice.Semantic proximity Read ↗

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Semantic proximity Read ↗

Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.